Genomma Lab Internacional, SAB de CV (BMV: LABB), a Mexico-based over-the-counter pharmaceutical, generic drugs and personal care products company, announced on Thursday a cash dividend of MXN0.200000 per share on its common stock.
This represents a total amount of MXN200m.
The dividend is payable to shareholders of record of the applicable circulating shares at the close of business on 14 March 2025.
Genomma Lab intends to make dividend payments on a quarterly basis.
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Veeda Group rebrands as 'Veeda Lifesciences'
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation
Induction Healthcare secures national video solution contract in Ireland
Safecor Health acquires Viatris' US unit-dose packaging business
LOG Pharma Primary Packaging opens new clean room
American Regent launches 30 mL Epinephrine Injection, USP in US